$DXCM

Heller Bridgette P sold $89K of DXCM

Heller Bridgette P sold 1,012 shares of DEXCOM INC (DXCM) at $88.29 on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heller Bridgette P
Published Aug 13, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DXCM
Neutral
high confidence
Mentioned
$DXCM
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

The only new fact is the director’s sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; no business or financial updates are included.

02

Market read

Traders may note the sale for sentiment monitoring, but it is unlikely to change valuation without additional company-specific news.

03

What to watch

10b5-1 plans can be triggered regardless of near-term outlook; the filing does not reveal intent beyond the scheduled trading window.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-13, sale dated 2026-08-12

Background

The article is a SEC Form 4 insider transaction disclosure for DexCom.

Company-level read

Ticker impact

$DXCMNeutralHigh confidence
Context

DexCom director Heller Bridgette P sold 1,012 shares at $88.29 on 2026-08-12 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone.

Evidence & confidence

The filing is a Form 4 insider open-market sale, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying guidance, contract, or operational change disclosed.

Market effects

Minimal, as this is an individual director’s 10b5-1 sale with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A cluster of insider sales (if corroborated by other recent Form 4s) could still reflect private caution, even when executed via 10b5-1.

Key entities

  • DexCom Inc

    Subject of the Form 4 insider sale disclosure.

  • Heller Bridgette P

    Director who sold 1,012 shares at $88.29 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DXCMHighAI 8/10

DexCom stock hits 52-week high at 91.99 USD

DexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.

$DXCMMed

Is Wall Street Bullish or Bearish on DexCom Stock?

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.